The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1768
Weltruza — A Once-Monthly Subcutaneous Formulation of Olanzapine
PDF:   US English
Disclosures
Principal Faculty
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
Additional Contributor(s)
  • Brinda M. Shah, Pharm.D., Consulting Editor has disclosed no relevant financial relationships.
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Review the efficacy and safety of once-monthly subcutaneous olanzapine (Weltruza) for treatment of schizophrenia.
 Select a term to see related articles     Abilify   antipsychotics   aripiprazole   Aristada   Invega   Okedi   olanzapine   paliperidone   Perseris   Relprevv   Risperdal   risperidone   Rykindo   schizophrenia   Uzedy   Weltruza   Zyprexa 
Med Lett Drugs Ther. 2026 Nov 23;68(1768):187-8   doi:10.58347/tml.2026.1768b

Weltruza (Teva), a once-monthly subcutaneous (SC) formulation of the second-generation antipsychotic drug olanzapine, has been approved by the FDA for treatment of schizophrenia in adults. A long-acting intramuscular (IM) formulation of olanzapine (Zyprexa Relprevv) is approved for the same indication.

Pronunciation Key
Weltruza: wel troo zah

LONG-ACTING INJECTABLE ANTIPSYCHOTICS — Long-acting injectable second-generation antipsychotic drugs (see Table 1) are generally used in patients with a history of poor adherence to oral maintenance therapy. They can improve adherence, hospitalization and relapse rates, and long-term outcomes in patients with schizophrenia.1,2

CLINICAL STUDIES — FDA approval of the SC formulation was based on the results of earlier trials with oral olanzapine and one unpublished double-blind trial (summarized in the package insert) in patients 18-64 years old with schizophrenia who were randomized to receive SC olanzapine (318, 425, or 531 mg) or placebo once monthly for 8 weeks, followed by open-label treatment with SC olanzapine for up to 48 weeks. The least-squares mean change from baseline in the Positive and Negative Syndrome Scale (PANSS; a 30-item scale that measures schizophrenia symptoms, with higher scores indicating greater symptom severity; scores range from 30 to 210) total score at week 8 was significantly greater with olanzapine than with placebo (-21.8 with the 318-mg dose, -23.4 with the 425-mg dose, and -21.9 with the 531-mg dose vs -12.2 with placebo). Improvements in PANSS total scores were maintained through 48 weeks of treatment.

ADVERSE EFFECTS — Adverse effects of SC olanzapine were similar to those observed with IM olanzapine and included injection-site reactions, weight gain, extrapyramidal symptoms, and somnolence. Neuroleptic malignant syndrome (NMS) and drug reaction with eosinophilia and systemic symptoms (DRESS) can occur.

A boxed warning in the label of IM olanzapine about a risk of post-injection delirium/sedation syndrome (PDSS) states that the patient should be monitored after each dose; PDSS is thought to be caused by unintentional introduction of olanzapine into the bloodstream. No cases of PDSS were reported with SC olanzapine in the clinical trial and its label does not require post-injection monitoring for PDSS.

The labels of all second-generation antipsychotic drugs contain a boxed warning about an increased risk of death in older patients with dementia-related psychosis.

DOSAGE AND ADMINISTRATION — Weltruza is available in vials containing 318, 425, or 531 mg of olanzapine powder for reconstitution, which correspond to oral olanzapine daily doses of 10 mg, 15 mg, and 20 mg, respectively. The recommended starting dosage is based on the patient's current oral maintenance dosage of olanzapine. The drug should be injected subcutaneously once monthly into the abdomen by a healthcare provider. Supplementation with oral doses of olanzapine is not required during initial treatment with Weltruza.

Table 1. Some Long-Acting Injectable Second-Generation Antipsychotics
Drug
Some Formulations
Usual Adult Maintenance Dosage1,2
Cost3
Aripiprazole –
Abilify Maintena (Otsuka/Lundbeck)
Abilify Asimtufii
 
300, 400 mg syringes, vials
720, 960 mg syringes
 
400 mg IM once/month4
960 mg IM q2 months4,5
 
$2991.60
4487.40
Aripiprazole lauroxil – Aristada
(Alkermes)
441, 662, 882, 1064 mg syringes
441, 662, or 882 mg IM once/month or
882 mg IM q6 wks or
1064 mg IM q2 months6
1686.50
Olanzapine – Weltruza (Teva)
318, 425, 531 mg vials
318, 425, or 531 mg SC once/month
3950.00
Olanzapine pamoate – Zyprexa Relprevv
(Lilly)
210, 300, 405 mg vials
150, 210, or 300 mg IM q2 wks or
300 or 405 mg IM once/month
925.80
Paliperidone palmitate –
Invega Sustenna (Janssen)
Invega Trinza
Invega Hafyera
 
39, 78, 117, 156, 234 mg syringes
273, 410, 546, 819 mg syringes
1092, 1560 mg syringes
 
117, 156, or 234 mg IM once/month
410, 546, or 819 mg IM q3 months
1092 or 1560 mg IM q6 months
 
1827.40
5482.10
14,619.60
Risperidone – Risperdal Consta (Janssen)
generic
Rykindo (Luye)
Perseris (Indivior)
Uzedy (Teva)
12.5, 25, 37.5, 50 mg vials
 
25, 37.5, 50 mg kits
90, 120 mg kits
50, 75, 100, 125, 150, 200, 250 mg
syringes
25, 37.5, or 50 mg IM q2 wks7
 
25 mg IM q2 wks8 (max 50 mg)
90 or 120 mg SC once/month
50, 75, 100, or 125 mg SC once/month or
100, 150, 200, or 250 mg SC q2 months
1329.40
1061.80
1229.10
2174.10
2731.50
1. Dosage adjustments may be needed for renal or hepatic impairment or for drug interactions.
2. Initial dosage of long-acting formulations for schizophrenia is based on patient’s stable oral maintenance dosage. Dosage of Invega Trinza is based
on the previous dose of Invega Sustenna; dosage of Invega Hafyera is based on the previous dose of Invega Sustenna or Invega Trinza.
3. Approximate WAC for 4 weeks’ or 1 month’s treatment with the lowest usual adult dosage (2 months’ treatment with Abilify Asimtufii, 3 months’
treatment with Invega Trinza, 6 months’ treatment with Invega Hafyera). WAC = wholesaler acquisition cost or manufacturer's published price to
wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly.
October 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/policies/drug-pricing-policy.
4. The first dose should be given with oral aripiprazole 10-20 mg for 14 consecutive days.
5. In patients taking Abilify Maintena, Abilify Asimtufii can be given in place of the second or later doses of Abilify Maintena.
6. Either a single 675-mg IM dose of Aristada Initio and one 30-mg dose of oral aripiprazole or 21 days of oral aripiprazole should be given with the first
dose of Aristada.
7. The first dose should be given with 21 days of oral risperidone.
8. The first dose should be given with 7 days of oral risperidone.

CONCLUSION — Weltruza, the new long-acting subcutaneous formulation of olanzapine that is FDA-approved for treatment of schizophrenia, may be less likely than the long-acting intramuscular formulation of olanzapine (Zyprexa Relprevv) to cause post-injection delirium/sedation syndrome.

REFERENCES

  1. JM Kane et al. The use of long-acting injectables for people with schizophrenia: consensus panel recommendations for overcoming barriers and implementing treatment. Neurol Ther 2025; 14:2551. doi:10.1007/s40120-025-00838-3
  2. SJ Harrison et al. The role of long-acting injectable antipsychotics in the early treatment of schizophrenia. CNS Drugs 2026; 40:921. doi:10.1007/s40263-026-01294-9
Important Copyright and Disclaimer Message: The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited. Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited. By accessing and reading the attached content I agree to comply with US and international copyright law and these terms and conditions of The Medical Letter, Inc.

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
arrow to previous article
arrow to next article